Panacea Biotec in pact with Technology Development Board for financial assistance

Panacea Biotec Ltd is currently trading at Rs 254, up by Rs 22.9 or 9.91% from its previous closing of Rs 231.1 on the BSE. The scrip opened at Rs 238.9 and has touched a high and low of Rs 271.9 and Rs 236.15 respectively.
The company announced that it has sign an agreement with Technology Development Board (TDB),Govt. of India for providing the financial assistance of Rs 28.99 Crore for the "Development and commercialization of Dengue Tetravalent vaccine.
Panacea Biotec's collaboration with National Institutes of Health (NIH), USA has led to the development of an advanced Dengue Vaccine in India with proven safety in pre-clinical studies.
According to the results from clinical trials conducted by NIH, the candidate Dengue vaccine has been found to stimulate a strong immune response against all 4 serotypes in all age-groups and expected to be a single dose vaccine. Panacea Biotec has obtained Phase 1/11 Clinical trial permission from Drug Controller General of India, New Delhi. Clinical trial lots production is in advanced stages at Panacea Biotec's cGMP facility and clinical trials will be started by early 2018.
Comments
Post a Comment